Another New Home For Momelotinib As GSK Buys Sierra
Drug Major Pays $1.9bn To Boost Blood Cancer Pipeline
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.
You may also be interested in...
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.